Intercept Pharmaceuticals

Listing Websites about Intercept Pharmaceuticals

Filter Type:

Homepage - Intercept Pharmaceuticals

(2 days ago) Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites. Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed. Continue

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals - Wikipedia

(5 days ago) Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals Company Profile - Craft

(2 days ago) Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals LinkedIn

(8 days ago) Intercept Pharmaceuticals Pharmaceutical Manufacturing Morristown, New Jersey 49,821 followers Our mission is to build a healthier tomorrow …

Url: Visit Now

Category:  Pharmaceutical,  Health Detail Drugs


Intercept Pharmaceuticals, Inc. (ICPT) Stock Price, News, …

(6 days ago) Find the latest Intercept Pharmaceuticals, Inc. (ICPT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals, Inc. Company Profile

(3 days ago) Company Description: Intercept Pharmaceuticals looks to cut liver disease off at the pass. A biopharmaceutical company, Intercept Pharmaceuticals is developing, and seeking to commercialize, therapies to treat chronic liver disease. Its lead product candidate, obeticholic acid (OCA), is being developed to treat primary biliary cirrhosis, an

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are …

(7 days ago) Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives Average

(1 days ago) Intercept Pharmaceuticals Company Profile . Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals (ICPT) Stock Price, News & Info The …

(9 days ago) Intercept Pharmaceuticals, inc (ICPT) Q3 2021 Earnings Call Transcript Motley Fool Transcribers Nov 3, 2021 ICPT earnings call for the period ending September 30, 2021.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ICPT Stock Price Intercept Pharmaceuticals Inc. Stock Quote (U.S

(8 days ago) Intercept Pharmaceuticals stock price target cut to $74 from $97 at B. Riley FBR. Nov. 20, 2020 at 7:28 a.m. ET by Tomi Kilgore.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives Average …

(7 days ago) 2 days ago · About Intercept Pharmaceuticals . Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals, (ICPT) - Forbes

(9 days ago) Intercept Pharmaceuticals, Inc. is a development stage biopharmaceutical company. It focuses on the discovering, developing and commercializing of novel therapeutics to treat chronic liver

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


INTERCEPT PHARMACEUTICALS, INC. : ICPT Stock Price

(8 days ago) Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals Stock Forecast

(3 days ago) The Intercept Pharmaceuticals stock price gained 0.22% on the last trading day (Friday, 24th Jun 2022), rising from $13.53 to $13.56. , and has now gained 6 days in a row.It is not often that stocks manage to gain so many days in a row, and falls for a day or two should be expected. During the day the stock fluctuated 5.67% from a day low at $13.04 to a day high of …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals Announces Convertible Notes

(2 days ago) The initial conversion price of the New Notes represents a premium of approximately 25.00% over the last reported sale price of Intercept’s common stock on August 10, 2021. The New Notes will be

Url: Visit Now

Category:  Health Detail Drugs


Intercept NASH drug faces uphill battle if approved by FDA

(Just Now) Despite Intercept Pharmaceuticals’ obeticholic acid (OCA) having a stronger shot at its second attempt at approval in nonalcoholic steatohepatitis (NASH), experts are still cautious of its initial uptake prospects. Liver biopsy requirements either by the FDA or payers will delay use, and its safety profile will require prescriber training and

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals to relocate from NYC to Crum

(9 days ago) Intercept Pharmaceuticals, a biopharmaceutical company focusing on the development of drugs to treat chronic liver diseases, inked a 26,174-square-foot office lease in the Crum & Forster-owned building in Morristown, according to a Monday announcement from CBRE. The firm is relocating its global headquarters from 10 Hudson Yards in Manhattan to the …

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals Stock Forecast, Price & News

(6 days ago) Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Working at Intercept Pharmaceuticals Glassdoor

(3 days ago) Type: Company - Public (ICPT) Industry: Biotech & Pharmaceuticals. Revenue: $100 to $500 million (USD) Competitors: Unknown. We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals, Inc. Common Stock (ICPT)

(Just Now) About Intercept Pharmaceuticals, Inc. 10 HUDSON YARDS 37TH FLOOR, NEW YORK, New York, 10001, United States +1 646 747-1000 https://www.interceptpharma.com. Intercept Pharmaceuticals is a biotech

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Working at Intercept Pharmaceuticals: Employee Reviews

(Just Now) Reviews from Intercept Pharmaceuticals employees about Intercept Pharmaceuticals culture, salaries, benefits, work-life balance, management, job security, and more.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ICPT Intercept Pharmaceuticals Inc — Stock Price and Discussion

(4 days ago) Intercept Pharmaceuticals Inc NASDAQ Updated Jun 27, 2022 8:37 PM. ICPT 13.48 0.08 (0.59%). Post-Market 0.00 (0.00%)

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives Average

(7 days ago) About Intercept Pharmaceuticals . Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals Inc - Stock Quote ICPT

(Just Now) Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept sells international rights to liver drug in $400M deal

(4 days ago) Intercept Pharmaceuticals will sell rights to its liver disease drug Ocaliva outside of the U.S. to U.K.-based Advanz Pharma, which agreed to pay Intercept $405 million upfront in a deal announced by the companies Thursday. Intercept could receive another $45 million from Advanz should European regulators grant Ocavlia an extension of pediatric

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals, Inc. (ICPT) Stock Price Today, Quote

(6 days ago) A high-level overview of Intercept Pharmaceuticals, Inc. (ICPT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals Inc

(9 days ago) Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Pharmaceuticals News Markets Insider

(5 days ago) Intercept Pharmaceuticals News: This is the News-site for the company Intercept Pharmaceuticals on Markets Insider. A vertical stack of three evenly spaced horizontal lines. The word "Insider".

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ADVANZ PHARMA ADVANZ PHARMA

(1 days ago) LONDON, May 05, 2022 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, has signed an agreement with Intercept Pharmaceuticals, Inc. (“Intercept”) to acquire the majority of Intercept’s …

Url: Visit Now

Category:  Pharmaceutical,  Hospital Detail Drugs


Intercept Pharmaceuticals Announces Convertible Notes

(Just Now) Net of this repurchase and the previously announced convertible notes exchange, Intercept’s 2023 Notes have been reduced from $460.0 million principal balance to $113.7 million principal balance

Url: Visit Now

Category:  Health Detail Drugs


OCALIVA® (obeticholic acid) – Official Patient Website

(4 days ago) I agree to receive information from Intercept Pharmaceuticals about the diseases it treats and its products and services. I understand that my information may be used by Intercept, and companies working with Intercept, for marketing purposes; to conduct market research; and to develop future products, services and programs.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


ICPT Stock News INTERCEPT PHARMACEUTICALS Stock Price …

(3 days ago) According to the current price, Intercept Pharmaceuticals is 119.85% away from the 52-week low. What was the 52-week high for Intercept Pharmaceuticals stock? The high in the last 52 weeks of

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Why Intercept Pharmaceuticals Is Plunging Today The Motley Fool

(4 days ago) Shares of Intercept Pharmaceuticals ( ICPT -3.06%) are plunging on Friday after the company announced some bad news regarding its new drug application (NDA) for Ocaliva as a treatment for fibrosis

Url: Visit Now

Category:  Pharmaceutical,  Lung Detail Drugs


72 Intercept Pharmaceuticals Reviews Glassdoor

(9 days ago) Intercept Pharmaceuticals has an overall rating of 3.3 out of 5, based on over 82 reviews left anonymously by employees. 50% of employees would recommend working at Intercept Pharmaceuticals to a friend and 34% have a positive outlook for the business. This rating has been stable over the past 12 months.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs


Intercept Resources for Healthcare Professionals

(3 days ago) Request an MSL Visit. If you would like a visit from one of our medical science liaisons (MSL), send an email to [email protected] Please include your full name, city, state/region and country where you practice (so that we can inform the MSL in your area), the best way to reach you (email and phone number), and the topic of discussion.

Url: Visit Now

Category:  Health Detail Drugs


INTERCEPT PHARMACEUTICALS Stock Forecast & Predictions

(6 days ago) INTERCEPT PHARMACEUTICALS. 's earnings in 2022 is -$68,290,000.. On average, 5 Wall Street analysts forecast ICPT's earnings for 2022 to be -$80,510,973, with the lowest ICPT earnings forecast at -$152,703,468, and the highest ICPT earnings forecast at -$28,817,581.

Url: Visit Now

Category:  Pharmaceutical Detail Drugs

Popular Searched

 › State of mn careers

 › Trinity hospital medical records ohio

 › Harris county hospital bed capacity

 › Drugs to dry up mucus

 › Drug detox at walmart

 › Hair tests for drugs

 › Doctor office space for rent

 › Priority health provider number

 › Medicare part d formulary 2021

 › Mercy health find provider

Recently Searched

 › Edgepark medical supplies fax number

 › Hospitals in queens county

 › Home care assistance sarasota fl

 › Organic skin care lines

 › Louisiana healthcare connections fax number

 › Health advantage preferred drug list

 › Part d health insurance

 › Medicare 5 star health plans

 › Deaconess gateway hospital map

 › Drug abuse heart issues

FAQ about Intercept Pharmaceuticals

What does Intercept Pharmaceuticals do?

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases.

Does Intercept Pharmaceuticals stock have a buy or sell signal?

Some negative signals were issued as well, and these may have some influence on the near short-term development. The Intercept Pharmaceuticals stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal.

Is Intercept Pharmaceuticals on the verge of breakeven?

Consensus from 16 of the American Biotechs analysts is that Intercept Pharmaceuticals is on the verge of breakeven. They anticipate the company to incur a final loss in 2023, before generating positive profits of US$44m in 2024. Therefore, the company is expected to breakeven roughly 2 years from today.

What are analysts'price targets for Intercept Pharmaceuticals'stock?

17 Wall Street analysts have issued 1-year price targets for Intercept Pharmaceuticals' stock. Their forecasts range from $10.00 to $67.00. On average, they anticipate Intercept Pharmaceuticals' share price to reach $29.67 in the next year. This suggests a possible upside of 106.6% from the stock's current price.